Is Sienna Biopharmaceuticals (SNNA) a Sell? What does Guggenheim Think?

December 7, 2017 - By Louis Casey

 Is Sienna Biopharmaceuticals (SNNA) a Sell? What does Guggenheim Think?

Why Has Guggenheim Given Sienna Biopharmaceuticals (SNNA) a $21 Price Target

In a report shared with investors and clients today, Guggenheim analysts has initiated Sienna Biopharmaceuticals (SNNA) coverage with “Neutral” rating, and a $21 target price.

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) Ratings Coverage

Among 5 analysts covering Sienna Biopharmaceuticals (SNNA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Sienna Biopharmaceuticals has $50 highest and $28.0 lowest target. $34’s average target is 68.23% above currents $20.21 stock price. Sienna Biopharmaceuticals had 5 analyst reports since August 21, 2017 according to SRatingsIntel. J.P. Morgan initiated the stock with “Buy” rating in Monday, August 21 report. The rating was initiated by Guggenheim on Tuesday, December 5 with “Hold”.

The stock increased 0.25% or $0.05 during the last trading session, reaching $20.21. About 7,594 shares traded. Sienna Biopharmaceuticals, Inc. (SNNA) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The company has market cap of $402.81 million. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It currently has negative earnings. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair.

More notable recent Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) news were published by: Globenewswire.com which released: “Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results” on September 07, 2017, also Globenewswire.com with their article: “Nasdaq Welcomes Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) to The Nasdaq …” published on July 27, 2017, Businesswire.com published: “Sienna Biopharmaceuticals Announces $40 Million Series B Financing” on April 24, 2017. More interesting news about Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) were released by: Prnewswire.com and their article: “Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer” published on March 24, 2017 as well as Marketwatch.com‘s news article titled: “Sienna Biopharmaceuticals Inc.” with publication date: July 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.